BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 22150034)

  • 1. The History of the FDA's Fight for Consumer Protection and Public Health, by US Food and Drug Administration.
    Semler E
    Nurs Hist Rev; 2020 Sep; 28(1):199-202. PubMed ID: 31537731
    [No Abstract]   [Full Text] [Related]  

  • 2. Secret ingredients: who knows what's in your food?
    Nicole W
    Environ Health Perspect; 2013 Apr; 121(4):A126-33. PubMed ID: 23548708
    [No Abstract]   [Full Text] [Related]  

  • 3. Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread.
    Ajmera H; Lakhawat SS; Malik N; Kumar A; Bhatti JS; Kumar V; Gogoi H; Jaswal SK; Chandel S; Sharma PK
    Curr Protein Pept Sci; 2024; 25(4):307-325. PubMed ID: 38265408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases.
    Ashraf H; Solla P; Sechi LA
    Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.
    Gupta AK; Das S; Kamran M; Ejazi SA; Ali N
    Virulence; 2022 Dec; 13(1):903-935. PubMed ID: 35531875
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Meinita MDN; Harwanto D; Sohn JH; Kim JS; Choi JS
    Foods; 2021 Jul; 10(7):. PubMed ID: 34359532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical translation of immunomodulatory therapeutics.
    Nash A; Aghlara-Fotovat S; Hernandez A; Scull C; Veiseh O
    Adv Drug Deliv Rev; 2021 Sep; 176():113896. PubMed ID: 34324885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of phenolic compounds and immunomodulatory activity of areca nut extract from Aceh, Indonesia, against
    Sari LM; Hakim RF; Mubarak Z; Andriyanto A
    Vet World; 2020 Jan; 13(1):134-140. PubMed ID: 32158163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration.
    Bounthavong M; Devine EB; Christopher MLD; Harvey MA; Veenstra DL; Basu A
    Health Serv Res; 2019 Oct; 54(5):1055-1064. PubMed ID: 31313839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites.
    Leal MM; Sanz MM; Ferrando JRC; Martinez-Martinez F
    Daru; 2019 Jun; 27(1):379-387. PubMed ID: 30778915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Return on Public Investment in Detecting Adverse Drug Effects.
    Huybrechts KF; Desai RJ; Park M; Gagne JJ; Najafzadeh M; Avorn J
    Med Care; 2017 Jun; 55(6):545-551. PubMed ID: 28505041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs and Medical Devices: Adverse Events and the Impact on Women's Health.
    Carey JL; Nader N; Chai PR; Carreiro S; Griswold MK; Boyle KL
    Clin Ther; 2017 Jan; 39(1):10-22. PubMed ID: 28069260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A statewide controlled trial intervention to reduce use of unproven or ineffective breast cancer care.
    Pezzin LE; Laud P; Neuner J; Yen TW; Nattinger AB
    Contemp Clin Trials; 2016 Sep; 50():150-6. PubMed ID: 27521808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Policy and Cardiovascular Medicine.
    Ross JS; Kesselheim AS
    Circulation; 2015 Sep; 132(12):1136-45. PubMed ID: 26391294
    [No Abstract]   [Full Text] [Related]  

  • 15. Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies.
    Nelson LS; Loh M; Perrone J
    J Med Toxicol; 2014 Jun; 10(2):165-72. PubMed ID: 24414251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perception on adverse drug reaction reporting by physicians working in southern romania.
    Paveliu MS; Bengea-Luculescu S; Toma M; Paveliu SF
    Maedica (Bucur); 2013 Mar; 8(1):17-25. PubMed ID: 24023593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs: oral and systemic adverse effects.
    Bascones-Martinez A; Mattila R; Gomez-Font R; Meurman JH
    Med Oral Patol Oral Cir Bucal; 2014 Jan; 19(1):e24-31. PubMed ID: 23986016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Federal legislation and the advancement of neonatal drug studies.
    Wiles JR; Vinks AA; Akinbi H
    J Pediatr; 2013 Jan; 162(1):12-5. PubMed ID: 23110945
    [No Abstract]   [Full Text] [Related]  

  • 19. Learning about the safety of drugs--a half-century of evolution.
    Avorn J
    N Engl J Med; 2011 Dec; 365(23):2151-3. PubMed ID: 22150034
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.